Literature DB >> 3894520

Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.

H Nakajima, H Fujiwara, Y Takai, Y Izumi, S Sano, T Tsuchida, T Hamaoka.   

Abstract

In the present study we investigated some of the cellular mechanisms for the generation of macrophage-activating factor(s) (MAF) in immune responses to tumor antigens. C3H/HeN mice were immunized to syngeneic MH134 hepatoma or MCH-1-A1 fibrosarcoma by intradermal inoculation of viable tumor cells, followed by the surgical resection of the tumor. Spleen and lymph node cells from these tumor-immune mice were stimulated in vitro with the corresponding tumor cells, and supernatant from such a culture was tested for an ability to activate macrophages to exert their cytostatic and cytolytic activities as detected on tumor cells unrelated to immunizing tumors. Peritoneal adherent cells as a macrophage source, which were preincubated with supernatant from co-culture of tumor-unimmunized normal spleen and lymph node cells plus tumor cells, failed to exhibit any significant antitumor effect on unrelated X5563 tumor cells, whereas the addition of supernatant from cultures containing immune lymphocytes to adherent cells resulted in appreciably potent cytostatic and cytolytic effects on X5563 tumor cells, indicating the generation of MAF in culture supernatant. The activation of tumor-immune spleen and lymph node cells for MAF generation was tumor-specific, because anti-MH134- and anti-MCH-1-A1-immune lymphocytes produced MAF by the stimulation with the respective but not with the other alternative tumor cells. Such MAF production was abolished by treatment of tumor-immune spleen and lymph node cells with anti-Thy-1.2 or anti-Lyt-1.1 but not with anti-Lyt-2.1 antibody plus complement before culturing. These results indicate that the tumor-specific Lyt-1+2- T cell subset has a crucial role in generating MAF by which an adherent cell population as a source of macrophages acquires the potential for inducing a cytolytic as well as a cytostatic effect on tumor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894520

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.

Authors:  K I Naruo; S Hinuma; O Shiho; T Houkan; K Ootsu; K Tsukamoto
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

2.  The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.

Authors:  T Yoshioka; H Fujiwara; Y Takai; M Ogata; J Shimizu; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.

Authors:  H F Dullens; W Vuist; M Van der Maas; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.

Authors:  H Nakajima; Y Izumi; S Sugihara; Y Satoh; S Isumi; T Gotoh; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells.

Authors:  K Yoshida; T Tachibana
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

6.  Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice.

Authors:  Y Moriya; H Sato; K Ito; M Saito; T Yoshida; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: role of antigen-presenting cells and their surface class I and class II H-2 molecules.

Authors:  K Sakamoto; H Nakajima; J Shimizu; T Katagiri; C Kiyotaki; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481).

Authors:  S Kurakata; M Tomatsu; M Arai; H Arai; A Hishinuma; H Kohno; K Kitamura; T Kobayashi; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 9.  Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.

Authors:  G Forni; H Fujiwara; F Martino; T Hamaoka; C Jemma; P Caretto; M Giovarelli
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

10.  Modulation of immune response against tumor cells by the in vivo administration of an autoreactive Th clone.

Authors:  M Kubo; K Sano; I Fujisawa; Y Asano; T Tada
Journal:  Jpn J Cancer Res       Date:  1989-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.